11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression

Summary

This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with cancer that has spread to other parts of the body (metastatic). 11C-YJH08 is a small-molecule radiotracer that binds to receptors on cells (glucocorticoid receptor) so that they show up better on the PET scan. Systemic therapy (including enzalutamide) can cause more glucocorticoid receptors to be produced in tumor cells, which can make the tumor cells resist hormone therapies. If researchers can find a better way to detect whether glucocorticoid receptors are increasing during therapy, it may lead to more successful therapies using glucocorticoid receptor antagonists.

Conditions

• Castration-Resistant Prostate Carcinoma
• Metastatic Prostate Carcinoma
• Stage IV Prostate Cancer AJCC v8
• Stage IVA Prostate Cancer AJCC v8
• Stage IVB Prostate Cancer AJCC v8
• Solid Tumor, Adult
• Solid Tumor
• Metastatic Castration-resistant Prostate Cancer

Interventions

PROCEDURE

Computed Tomography

Undergo CT imaging

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

PROCEDURE

Positron Emission Tomography

Undergo PET imaging

DRUG

11C-YJH08

Given IV

PROCEDURE

Optional Tumor Biopsy

Optional procedure to obtain tumor tissue

Sponsors & Collaborators

• U.S. Army Medical Research Acquisition Activity

  collaborator FED

• National Institute of Mental Health (NIMH)

  collaborator NIH

• Rahul Aggarwal

  lead OTHER

Principal Investigators

• Rahul Aggarwal, MD · University of California, San Francisco

Study Design

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

18 Years

Sex

MALE

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-08-10

Primary Completion

2025-02-28

Completion

2025-02-28

FDA Drug

Yes

Countries

• United States

Study Locations